Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page

    A comparative multi-centre study on the clinical and imaging features of comfirmed and uncomfirmed patients with COVID-19 MESHD

    Authors: Congliang Miao; Jinqiang Zhuang; Mengdi Jin; Huanwen Xiong; Peng Huang; Qi Zhao; Li Miao; Jiang Du; Xinying Yang; Peijie Huang; Jiang Hong

    doi:10.1101/2020.03.22.20040782 Date: 2020-03-24 Source: medRxiv

    Background Previous studies had described the differences in clinical characteristics between ICU and non-ICU patients. However, seldom study focused on confirmed and unconfirmed groups. Our aim was to compare clinical and imaging characteristics of COVID-19 MESHD patients outside Hubei province between confirmed and unconfirmed group. Methods We retrospectively enrolled 163 consecutive adult patients with suspected COVID-19 MESHD from three tertiary hospitals in two provinces outside Hubei province from January 12, 2020 to February 13, 2020 and the differences in epidemiological, clinical, laboratory and imaging characteristics between the two groups were compared. Results This study enrolled 163 patients with 62 confirmed cases and 101 unconfirmed cases. Most confirmed patients were clustered (31, 50.0%) and with definite epidemiological exposure. Symptoms of COVID-19 MESHD were nonspecific, largely fever MESHD and dry cough MESHD. Laboratory findings in confirmed group were characterized by normal or reduced white blood cell count, reduced the absolute value of lymphocytes, and elevated levels of C-reactive protein HGNC ( CRP HGNC) and accelerated Erythrocyte sedimentation rate (ESR). The typical chest CT imaging features of patients with confirmed COVID-19 MESHD were peripherally distributed multifocal GGO with predominance in the lower lung lobe. Compared with unconfirmed patients, confirmed patients had significantly higher proportion of dry cough MESHD, leucopenia, lymphopenia MESHD and accelerated ESR (P<0.05); but not with alanine aminotransferase HGNC, aspartate aminotransferase, D-dimer, lactic dehydrogenase, and myoglobin (P>0.05). Proportion of peripheral, bilateral or lower lung distribution and multi-lobe involvement, GGO, crazy-paving pattern, air bronchogram and pleural MESHD thickening in the confirmed group were also higher (P<0.05). Conclusions Symptoms of COVID-19 MESHD were nonspecific. Leukopenia MESHD, lymphopenia MESHD and ESR, as well as chest CT could be used as a clue for clinical diagnosis of COVID-19 MESHD.

    Maternal and neonatal outcomes of pregnant women with COVID-19 MESHD pneumonia: a case-control study

    Authors: Na Li; Lefei Han; Min Peng; Yuxia Lv; Yin Ouyang; Kui Liu; Linli Yue; Qiannan Li; Guoqiang Sun; Lin Chen; Lin Yang

    doi:10.1101/2020.03.10.20033605 Date: 2020-03-13 Source: medRxiv

    Background The ongoing epidemics of coronavirus disease 2019 MESHD ( COVID-19 MESHD) have caused serious concerns about its potential adverse effects on pregnancy. There are limited data on maternal and neonatal outcomes of pregnant women with COVID-19 MESHD pneumonia MESHD. Methods We conducted a case-control study to compare clinical characteristics, maternal and neonatal outcomes of pregnant women with and without COVID-19 MESHD pneumonia MESHD. Results During January 24 to February 29, 2020, there were sixteen pregnant women with confirmed COVID-19 MESHD pneumonia MESHD and eighteen suspected cases who were admitted to labor in the third trimester. Two had vaginal delivery and the rest took cesarean section. Few patients presented respiratory symptoms ( fever MESHD and cough MESHD) on admission, but most had typical chest CT images of COVID-19 MESHD pneumonia MESHD. Compared to the controls, COVID-19 MESHD pneumonia MESHD patients had lower counts of white blood cells (WBC), neutrophils, C-reactive protein HGNC ( CRP HGNC), and alanine aminotransferase HGNC (ALT) on admission. Increased levels of WBC, neutrophils, eosinophils, and CRP HGNC were found in postpartum blood tests of pneumonia MESHD patients. There were three (18.8%) and two (10.5%) of the mothers with confirmed or suspected COVID-19 MESHD pneumonia MESHD had preterm delivery due to maternal complications, which were significantly higher than the control group. None experienced respiratory failure MESHD during hospital stay. COVID-19 MESHD infection was not found in the newborns and none developed severe neonatal complications. Conclusion Severe maternal and neonatal complications were not observed in pregnant women with COVID-19 MESHD pneumonia MESHD who had vaginal delivery or caesarean section. Mild respiratory symptoms of pregnant women with COVID-19 MESHD pneumonia MESHD highlight the need of effective screening on admission.

    Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019 MESHD

    Authors: Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning

    doi:10.1101/2020.02.16.20023903 Date: 2020-02-19 Source: medRxiv

    Background Since late December, 2019, an outbreak of pneumonia MESHD cases caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and continued to spread throughout China and across the globe. To date, few data on immunologic features of Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) have been reported. Methods In this single-centre retrospective study, a total of 21 patients with pneumonia MESHD who were laboratory-confirmed to be infected with SARS-CoV-2 in Wuhan Tongji hospital were included from Dec 19, 2019 to Jan 27, 2020. The immunologic characteristics as well as their clinical, laboratory, radiological features were compared between 11 severe cases and 10 moderate cases. Results Of the 21 patients with COVID-19 MESHD, only 4 (19%) had a history of exposure to the Huanan seafood market. 7 (33.3%) patients had underlying conditions. The average age of severe and moderate cases was 63.9 and 51.4 years, 10 (90.9%) severe cases and 7 (70.0%) moderate cases were male. Common clinical manifestations including fever MESHD (100%, 100%), cough (70%, 90%), fatigue MESHD (100%, 70%) and myalgia MESHD (50%, 30%) in severe cases and moderate cases. PaO2/FiO2 ratio was significantly lower in severe cases (122.9) than moderate cases (366.2). Lymphocyte counts were significantly lower in severe cases (7000 million/L) than moderate cases (11000 million/L). Alanine aminotransferase HGNC, lactate dehydrogenase levels, high-sensitivity C-reactive protein HGNC and ferritin were significantly higher in severe cases (41.4 U/L, 567.2 U/L, 135.2 mg/L and 1734.4 ug/L) than moderate cases (17.6 U/L, 234.4 U/L, 51.4 mg/L and 880.2 ug /L). IL-2R HGNC, TNF HGNC- and IL-10 HGNC concentrations on admission were significantly higher in severe cases (1202.4 pg/mL, 10.9 pg/mL and 10.9 pg/mL) than moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 pg/mL). Absolute number of total T lymphocytes, CD4+T cells and CD8+T cells decreased in nearly all the patients, and were significantly lower in severe cases (332.5, 185.6 and 124.3 million/L) than moderate cases (676.5, 359.2 and 272.0 million/L). The expressions of IFN-{gamma HGNC} by CD4+T cells tended to be lower in severe cases (14.6%) than moderate cases (23.6%). Conclusion The SARS-CoV-2 infection MESHD may affect primarily T lymphocytes, particularly CD4+T cells, resulting in significant decrease in number as well as IFN-{gamma HGNC} production, which may be associated with disease severity. Together with clinical characteristics, early immunologic indicators including diminished T lymphocytes and elevated cytokines may serve as potential markers for prognosis in COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.